Skip to main content
Journal cover image

Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada.

Publication ,  Journal Article
Matos, JD; McIlvaine, S; Grau-Sepulveda, M; Jawitz, OK; Brennan, JM; Khabbaz, KR; Sellke, FW; Yeh, R; Zimetbaum, P
Published in: The Journal of thoracic and cardiovascular surgery
August 2021

We sought to elucidate national practice patterns regarding anticoagulation and antiarrhythmic medication use at discharge and examine short-term patient outcomes.In this retrospective cohort study, we analyzed the data of patients from the Society of Thoracic Surgeons Adult Cardiac Surgery Database from July 2011 to June 2018 who underwent first-time isolated coronary artery bypass graft surgery (CABG) and developed new post-CABG atrial fibrillation (AF) without significant complications. In total, 166,747 patients met study criteria. We examined 30-day outcomes.In total, 166,747 patients were analyzed and divided into 4 groups based on discharge medications: amiodarone with or without anticoagulation, anticoagulation alone, and neither. Demographic characteristics were similar among the 4 groups. In total, 25.7% of patients were discharged on anticoagulation with an average CHA2DS2-VASc score of 3.2 ± 1.3. Anticoagulation use at discharge was not associated with lower 30-day stroke readmissions (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.65-1.16; P = .35). Adjusted 30-day readmissions for major bleeding were significantly more common in anticoagulated patients (AOR, 4.30; 95% CI, 3.69-5.03; P < .0001). Among those discharged off anticoagulation, there was no significant difference in adjusted 30-day stroke rates based on amiodarone use at discharge (AOR, 1.19; 95% CI, 0.85-1.66; P = .31).Post-CABG anticoagulation for new AF is associated with increased bleeding and no difference in stroke at 30 days. Prospective randomized studies are needed to formalize safe and efficacious short- and long-term management strategies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The Journal of thoracic and cardiovascular surgery

DOI

EISSN

1097-685X

ISSN

0022-5223

Publication Date

August 2021

Volume

162

Issue

2

Start / End Page

616 / 624.e3

Related Subject Headings

  • United States
  • Treatment Outcome
  • Time Factors
  • Stroke
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Respiratory System
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Matos, J. D., McIlvaine, S., Grau-Sepulveda, M., Jawitz, O. K., Brennan, J. M., Khabbaz, K. R., … Zimetbaum, P. (2021). Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. The Journal of Thoracic and Cardiovascular Surgery, 162(2), 616-624.e3. https://doi.org/10.1016/j.jtcvs.2020.01.077
Matos, Jason D., Susan McIlvaine, Maria Grau-Sepulveda, Oliver K. Jawitz, J Matthew Brennan, Kamal R. Khabbaz, Frank W. Sellke, Robert Yeh, and Peter Zimetbaum. “Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada.The Journal of Thoracic and Cardiovascular Surgery 162, no. 2 (August 2021): 616-624.e3. https://doi.org/10.1016/j.jtcvs.2020.01.077.
Matos JD, McIlvaine S, Grau-Sepulveda M, Jawitz OK, Brennan JM, Khabbaz KR, et al. Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. The Journal of thoracic and cardiovascular surgery. 2021 Aug;162(2):616-624.e3.
Matos, Jason D., et al. “Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada.The Journal of Thoracic and Cardiovascular Surgery, vol. 162, no. 2, Aug. 2021, pp. 616-624.e3. Epmc, doi:10.1016/j.jtcvs.2020.01.077.
Matos JD, McIlvaine S, Grau-Sepulveda M, Jawitz OK, Brennan JM, Khabbaz KR, Sellke FW, Yeh R, Zimetbaum P. Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. The Journal of thoracic and cardiovascular surgery. 2021 Aug;162(2):616-624.e3.
Journal cover image

Published In

The Journal of thoracic and cardiovascular surgery

DOI

EISSN

1097-685X

ISSN

0022-5223

Publication Date

August 2021

Volume

162

Issue

2

Start / End Page

616 / 624.e3

Related Subject Headings

  • United States
  • Treatment Outcome
  • Time Factors
  • Stroke
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Respiratory System
  • Middle Aged
  • Male